I think Napadono has it correct. The JPM conference is coming up very soon and all attendees want to have a very positive outlook as far as their current cash supply.
Search "The debtor’s perspective: an overview of the options available to a company facing distress" to better understand the various bankruptcy filings and their differences.
Understanding the situation at hand. An excerpt from the web:
In its most general sense, a pre-arranged bankruptcy typically refers to a restructuring that is:
• negotiated with representatives of the most significant constituencies that are expected to be impaired
(usually the senior lenders, bondholders or principal equity holders);
• agreed to by some or all of those representatives;
• memorialized in a written agreement setting forth all or most of the definitive terms of a plan of reorganization.
The most significant differences between the two approaches (pre-packaged and pre-arranged) are that in the pre-arranged plan context, the major constituencies usually enter into a lock-up agreement whereby they commit to support the plan process, but the OFFICIAL SOLICITATION of votes is not commenced until after the commencement of the Chapter 11 case itself. Pre-packaging or pre-arranging a Chapter 11 reorganization enables a debtor to minimize the negative impact on its ongoing business operations by combining many of the best aspects of out-of court workouts (eg, cost, efficiency, speed, flexibility and cooperation) with the binding effect and structure of a conventional bankruptcy.
All may not be lost, yet. Sounds like there will be some negotiations to deal with in the future.
What do you expect from someone who was born with the middle of their anatomy positioned on their shoulders. Definitely a low class individual that lives under a rock somewhere!
Look a little harder by searching for his hunting buddy, too. His partner's name is Dial Dunkin. Now that's what I call a sizeable leopard!
Time to buy more shares is coming soon. GLTA.
From Motley Fool:
What: After shares surged more than 60% yesterday following its oil rally, shares of Magnum Hunter Resources sank by as much as 20% today following the announcement that it has signed a letter of intent to farm out some of its nondeveloped acreage in the Utica shale formation to a private equity.
So what: Magnum Hunter is one of the poster children for companies that take on too much debt to try to fuel massive oil and gas production when prices are high, only to find themselves strapped for cash when prices crash. Over the past year, shares of Magnum Hunter are down more than 80%. Now, the slightest change in oil and gas prices will swing Magnum Hunter's stock in wild directions.
On top of this immense oil and gas volatility, the company announced today that it is agreeing to farm out 9,500 acres of its undeveloped acreage in the Utica formation to a private equity company. Under the deal, Magnum Hunter will receive a small cash injection and the private equity company will retain the rights to drill up to $400 million worth of wells on that acreage. Once the private equity company generates a 12% internal rate of return, the wells will then be returned and any residual production will go to Magnum Hunter.
Now what: Chances are, today's movement is much more related to oil and gas prices rather than the announcement of this private equity deal, because this deal is likely a good thing for the company. It allows Magnum Hunter to monetize the asset and turn it into a producing asset further down the road once private equity gets its cut. It will likely be lower-production, but it's almost free development. Also, the $25 million in cash the company will get to complete this deal is much needed for a company that has only generated $14 million in operational cash flow over the past 12 months.
Per above, GE has started to bring in some much needed funds. Enjoy.
They will probably sell all the necessary stock and to avoid wash-sale wait at least 30 days before buying back in. Oil and gas should remain low for a while and may in fact spike up sharply once exports and the new utilities start coming on line. The gas companies have been buying more. Appears that Relational is trying to get this all in before year end and the possible pipeline sale, etc.
Please excuse the poor formatting above. Double-clicked when I shouldn't have. Here's something else I found that may be of interest:
As of Mar 21, 2015, the consensus forecast amongst 4 polled investment analysts covering Epirus Biopharmaceuticals Inc. advises investors to purchase equity in the company. This has been the consensus forecast since the sentiment of investment analysts improved on Jul 21, 2014. The previous consensus forecast advised investors to hold their position in Epirus Biopharmaceuticals Inc.
You can get on the bus or remain at the station. Do your own DD. The biosimilar market is getting quite interesting.
Closed a $36 million Series B financing round
Completed merger with Zalicus Inc.; Gained
public listing on Nasdaq:EPRS
Entered into a multi-product collaboration
agreement with Livzon Mabpharm for China
BOW015 approved and launched in first
market, India, under the trade name Infimab™
In 2015 and beyond:
Completed $52.8M follow on offering – 1Q15
BOW015 additional market filings and partnerships (LATAM, Asia) – Filings throughout 2015
BOW050 partnership(s) – 1H15
BOW015 US / EU partnership – 2H15
Initiation of BOW015 global phase 3 – 4Q15/1Q16
BOW050 enters clinical trials – 2H16
BOW015 launches in multiple South East Asian markets – throughout 2016
What do you know. The stock is up a couple of bucks since I last visited here. Hopefully, we'll hear some good news when they report next week on the 12th.
TTMA as someone here used to say!
Isn't an investment in any stock hopeful?
You mention one of their partners (Ranbaxy) that will be sharing the proceeds but leave out others like Reliance Life Sciences (RLS), Fujifilms and Livzon. RLS will be the actual manufacturer in India. Ranbaxy is a partner that affords them real good access due to their size and exposure to 150 countries.
How about their trademarked SCALE platform? It allows for multiple biosimilar drugs to be made in the same facility which will cut manufacturing costs effectively.
The reasons for partnering with all these different entities: there are basically three types of drug Markets. Developed, Local Production and Accessible. These all of have specific rules such as where the medicine must be produced or tested (e.g., locally). An accessible market, such as India, will furnish EPRS with an Indian regulatory package. The regulatory filing from India MAY be all that is needed to allow the drug to be sold in a country like Brazil, without any phase testing whatsoever. The Indian regulatory package is readily accepted in countries such as Africa, southeastern Asia and South & Central America (excluding Brazil).
Livzon is their Chinese partner and they have invested heavily in EPRS already, during the IPO.
So yes, I guess you could say that I have "hopium". I also don't plan on selling any time soon. Just want other ZBAers to look into what EPRS is doing and how they are laying the groundwork. They appear to be creating a rather large scale plan. My opinion only.
I would bet that more than 99% of us know the whole story. Former ZLCS holders that are still here are the ones that are praying for a turnaround.
- EPRS also hooked up with ZLCS because they knew the "ropes" in getting listed quickly for funding purposes.
- Wrong-way Corrigan has some expertise in getting a drug to market (Exalgo) and how to navigate through phase approvals.
- ZLCS was well respected at one time, had some cash to give out and did have connections in certain areas.
- EPRS stock has taken off at times due to India approval of BOW015 and future European phase 3 approval. They also have Asian, African, etc. markets as near term market possibilities.
- The biosimilar drugs that EPRS has in its stable are "big money maker" name brands (Remicade, Humira and Actemra).
There are probably some other points that I cannot think of off hand but these seem to be some of the main reasons for the price spikes.
Which is exactly why I, a Zalicus holdover who is down some bucks, decided to add shares of EPRS a few months ago. I figured it was the only way I could regain some of my losses. I did the same thing with SUV a few years ago and went from the out house to the bank. All of you former big 'Z'ers should think about getting your feet wet again. This is just my opinion, and think of all the fun you'll have again. Sleepless nights, worrying about whether or not the drug will pass phase 3, etc. Heck, the Dawg may even show himself again and entertain us with a lot of his research that he's done on biosimilars over the past couple of years. Food for thought!
My old ZLCS average was around $68 for break even, but then I had a premonition and wound up buying some more shares later when they were around $3.70. That took my average down to $38 afterwards. I'm getting closer to breaking even and hopefully I'll be able to finally bail on this after we have some sales in India. Keep going Zalicepirus!!!
Does this even have a chance to occur in 2014?
EPIRUS is a Boston-based, privately held company, backed by Montreux Equity Partners, TPG
Biotech, and 5AM Ventures. EPIRUS is developing a broad pipeline of biosimilars for commercialization in major emerging markets. Our first product is BOW015, a biosimilar to Remicade®. BOW015 has successfully completed P1 and P3 clinical trials. We anticipate first market approval and launch in 2014.
Zalicus to Present at AACR 2014 Annual Meeting
Zalicus and Collaborators Eisai and Sanofi Leverage Combination High-Throughput Screening Platform to Evaluate Combination Drug Synergies
Slug: I was hoping you'd see the light some day. Excerpt from the Trib:
After thousands of innings of watching (mostly losing) baseball at Wrigley Field, I have finally found kind words for the White Sox, and I mean them sincerely: Your beer menu is better than ours. A lot better.
Though both parks continue to be dominated by macro brands (Budweiser up north and Miller to the south), where U.S. Cellular Field pummels Wrigley like a Carlos Marmol slider that forgot to slide is in the diversity of its menu.
The Cell boasts a legitimate lineup of craft beer. OK, it's not quite worthy of a craft beer bar, but for nine innings I have no problem sipping my way through a Sox game (which I do a couple of times a season for love of baseball, if not the White Sox). A healthy number of Sox fans agree.
Man, to have to endure the stress I've experienced over the past 4 years holding Z for the rest of my life as a ZBAer would be the pits. I think I would surrender and start taking the opioids then.
Here's another joke for you:
If 80% of all Asian doctors have cataracts what do the other 20% have?